Work

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Year: 2013

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v122.21.4396.4396

Authors: Sheeba K. Thomas, Tamara M Haygood, Muzaffar H. Qazilbash, A. Georgina Melendez, Roxana Galvis, Kay B Delasalle, Lei Feng, Tiffany A. Richards, Felipe Samaniego, Luhua Wang, Jatin J. Shah, Robert Z. Orlowski, Donna M. Weber

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2468154395

FWCI:

Cites:

Cited by:

Related to: 10